Sutro Biopharma (STRO) to Release Earnings on Thursday

Sutro Biopharma (NASDAQ:STRO) will likely be posting its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Sutro Biopharma to announce earnings of ($2.2204) per share and revenue of $11.7760 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, August 14, 2026 at 12:30 PM ET.

Sutro Biopharma (NASDAQ:STRO) last released its quarterly earnings results on Thursday, May 14th. The company reported ($2.94) earnings per share for the quarter, missing the consensus estimate of ($2.74) by ($0.20). The firm had revenue of $14.52 million during the quarter, compared to analysts’ expectations of $8.89 million. On average, analysts expect Sutro Biopharma to post $-9 EPS for the current fiscal year and $-7 EPS for the next fiscal year.

Sutro Biopharma Price Performance

STRO stock opened at $23.32 on Thursday. The company has a market cap of $386.41 million, a P/E ratio of -2.11 and a beta of 1.51. Sutro Biopharma has a 1 year low of $7.15 and a 1 year high of $43.85. The stock’s fifty day moving average price is $27.75 and its 200-day moving average price is $25.16.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Barclays assumed coverage on Sutro Biopharma in a report on Thursday, May 28th. They issued an “overweight” rating and a $56.00 target price on the stock. HC Wainwright boosted their price target on Sutro Biopharma from $28.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, May 15th. Lifesci Capital raised shares of Sutro Biopharma to a “strong-buy” rating in a research report on Friday, May 1st. Mizuho set a $50.00 price objective on shares of Sutro Biopharma and gave the stock an “outperform” rating in a research note on Thursday, April 30th. Finally, Truist Financial started coverage on shares of Sutro Biopharma in a report on Thursday, June 11th. They issued a “buy” rating and a $50.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $52.44.

Institutional Trading of Sutro Biopharma

Several hedge funds have recently bought and sold shares of the stock. AQR Capital Management LLC increased its position in Sutro Biopharma by 1,052.8% in the first quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company’s stock worth $859,000 after buying an additional 1,206,330 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Sutro Biopharma during the 2nd quarter valued at about $492,000. Jacobs Levy Equity Management Inc. purchased a new position in shares of Sutro Biopharma during the 3rd quarter valued at about $387,000. Two Sigma Investments LP grew its stake in shares of Sutro Biopharma by 244.8% during the 3rd quarter. Two Sigma Investments LP now owns 396,785 shares of the company’s stock valued at $345,000 after acquiring an additional 281,717 shares during the period. Finally, Marshall Wace LLP bought a new position in shares of Sutro Biopharma during the 2nd quarter valued at approximately $166,000. Institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.